Alstom sinks on the stock market after lowering forecasts
Alstom (ALO IM) shares fell 26.63% to €11.60 after lowering its fiscal year forecasts. The company now expects an adjusted operating margin of 1% (down from 6.5%) and reduced train production to 4,000 units. Free cash flow is projected to be -€1.5B. Issues include certification delays and cost overruns on the Coradia Max platform, as well as broader project execution difficulties.
How this was made

The 30-second read
Why it matters
The forecast cut is material: adjusted operating margin guidance drops sharply, free cash flow guidance turns from positive to a large negative, and turnover growth projections are reduced. The operational causes cited (certification delays, cost overruns, and other Germany-linked projects affected) increase perceived execution risk across the group.
Market read
Traders can act on a fresh guidance reset with quantified margin and cash-flow impacts, which typically drives immediate repricing and volatility.
What to watch
The company still expects train production around 4,000 units; traders may focus on whether the certification and cost overruns are contained to specific platforms rather than the whole order book.
Background
Alstom is a French railway equipment supplier, and the article frames the downgrade around profitability issues in the first half and execution problems tied to certification and the Coradia Max platform.
Market effects
Rail equipment and rolling-stock peers may see read-across selling on execution and certification/cost-overrun risk.
Could weigh on European industrials/transport equipment sentiment in the near term.
Limited direct global spillover, but it can affect investor risk appetite for capital goods with long project cycles.
Counterpoint
Some deterioration may be timing-related (the article cites seasonality for H1 free cash flow), so the market may over-discount if margins normalize later in the year.
Key entities
- companyAlstom
Railway equipment company that lowered FY forecasts due to profitability problems, certification delays, and cost overruns on Coradia Max.


